oxaliplatin

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Colonic Neoplasms

Conditions

Colonic Neoplasms

Trial Timeline

Aug 1, 2004 → —

NCT ID

NCT00263055

About oxaliplatin

oxaliplatin is a approved stage product being developed by Sanofi for Colonic Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00263055. Target conditions include Colonic Neoplasms.

What happened to similar drugs?

1 of 2 similar drugs in Colonic Neoplasms were approved

Approved (1) Terminated (1) Active (1)

✅Methylnaltrexone Bromide (MNTX) + PlaceboPfizerApproved

🔄Oxaliplatin (SR96669)SanofiPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (12)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00238849	Phase 2	UNKNOWN	—	—	Previously Treated Metastatic Non-Small Cell Lung Cancer
NCT00846482	Pre-clinical	Completed	Feb 1, 2008	Dec 1, 2018	Colon Cancer
NCT00261092	Phase 2	Completed	Oct 1, 2005	—	Pancreatic Neoplasms
NCT00129870	Approved	Terminated	Feb 1, 2005	Dec 1, 2007	Colorectal Cancer
NCT00256308	Phase 2	Terminated	Feb 1, 2005	Oct 1, 2011	Head and Neck Cancer
NCT00263055	Approved	Completed	Aug 1, 2004	—	Colonic Neoplasms
NCT00280618	Phase 2	Completed	Jul 1, 2004	—	Carcinoma, Hepatocellular
NCT00263354	Phase 2	Completed	Oct 1, 2003	Jul 1, 2006	Stomach Neoplasms
NCT01042691	Phase 1	Completed	May 1, 2003	Nov 1, 2011	Unresectable Colorectal Liver Metastases
NCT00174564	Phase 2	Completed	Apr 1, 2003	Sep 1, 2006	Biliary Tract Neoplasms
NCT00259363	Phase 1/2	Terminated	Oct 1, 2002	—	Rectal Neoplasms
NCT00403624	Phase 1/2	Completed	Jul 1, 2001	Nov 1, 2005	Rectal Neoplasms

Competing Products

6 competing products in Colonic Neoplasms

See all competitors

Product	Company	Stage	Hype Score
Enzastaurin HCl	Eli Lilly	Phase 2	35
Entereg + Entereg + placebo	Merck	Phase 2	35
Indium labeled IMP-205xm734	Gilead Sciences	Phase 1	29
psyllium fibre (dietary supplement) + wheat bran (dietary supplement) + rice wheat (placebo)	Pfizer	Pre-clinical	26
Methylnaltrexone Bromide (MNTX) + Placebo	Pfizer	Approved	35
Oxaliplatin (SR96669)	Sanofi	Phase 3	40